FLT4 (800-end), active, GST tagged human
SIGMA/SRP5210 - PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution
Synonym: FLT41; LMPH1A; PCL; VEGFR3
Product Type: Chemical
SDS-PAGE FLT4 (800-end), active, GST tagged, human: Cat. No. SRP5210: Purity was determined by densitometry. Molecular weight ~85 kDa. See CofA for lot-specific data.
Specific Activity FLT4 (800-end), active, GST tagged, human: Cat. No. SRP5210: Specific Activity was determined by activity assay (see datasheet for protocol). See CofA for lot-specific data.
| assay | ≥70% (SDS-PAGE) |
| form | buffered aqueous glycerol solution |
| mol wt | ~85 kDa |
| NCBI accession no. | NM_002020   |
| product line | PRECISIO® Kinase |
| recombinant | expressed in baculovirus infected Sf9 cells |
| shipped in | dry ice |
| specific activity | 57.8-78.2 nmol/min·mg |
| storage temp. | −70°C |
| General description: | FLT4 or fms-related tyrosine kinase 4 is a tyrosine kinase receptor for vascular endothelial growth factors C and D and highly expressed in lymphangiogenesis and maintenance of the lymphatic endothelium. FLT4 is a marker for lymphatic vessels and some high endothelial venules in human adult tissues and also supported the theory of the venous origin of lymphatic vessels. FLT4 plays an essential role in the development of the embryonic cardiovascular system before the emergence of the lymphatic vessels. |
| Legal Information: | PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany |
| Physical form: | Supplied in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. |
| Preparation Note: | after opening, aliquot into smaller quantities and store at -70 °C. Avoid repeating handling and multiple freeze/thaw cycles |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Purity | ≥70% (SDS-PAGE) |
| activity | specific activity: 57.8-78.2 nmol/min·mg |
| Storage Temp. | −70°C |
| UNSPSC | 12352200 |